Web27 Jan 2024 · Long-term antithrombotic therapy for the secondary prevention of ischemic stroke; Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors; Management and prevention of rheumatic heart disease; Management of late complications of head and neck cancer and its treatment WebIn the secondary prevention of cardiovascular diseases, results showed that pravastatin and atorvastatin could reduce the incidence of major CVEs by 13% and 41%, respectively, compared with the control group, but there was no significant difference between other statins and control ( Table 2 ). In 10 head–head studies, 45 – 54 the influence ...
Lipid Modification for Non-familial Hypercholesterolaemia (Adults)
Web21 Oct 2024 · 20-25% when added to statin therapy. Consider dual lipid-lowering therapy in patients with baseline LDL-C >100 mg/dL. Treatment goals. Evolocumab. LDL-C <55 mg/dL AND a 50% reduction of baseline LDL. 140 mg s.c. every other week; 420 mg s.c. monthly. 50-60% as add-on. Refer to specialist. Treatment goals. WebThe evidence is that statins are effective in reducing heart attacks and stroke, both fatal and non-fatal. This reduction occurred consistently in large randomised trials with event rates for the combined outcome of fatal or nonfatal heart attack or stroke over five years of 10 to 35%. This corresponds to a 10-year risk of 20 to 70%. slowfast facebook
Clinician Guide to the ABCs of Primary and Secondary Prevention …
WebReview medications used in secondary prevention: Antiplatelet therapy is initiated by secondary care on diagnosis of ischaemic stroke or TIA without paroxysmal or permanent … Webstatins was associated with a decline in cognition function.10 Statin dose Meta-analyses suggest that 80% of the lipid-lowering effect of statins occurs at half the maximal statin dose.11 In older patients, the efficacy of statins for secondary prevention of acute myocardial infarction and death appears to be a class effect, with no WebIn the Cholesterol Treatment Trialists’ Collaboration meta-analysis of 28 RCT, the evidence for patients >75 years old taking statins for primary prevention was not strong (RR 0.92 per 1 mmol/L LDL reduction, CI: 0.72-1.16), as opposed to secondary prevention with a 26% proportional reduction of major vascular events per 1 mmol/L reduction in ... slowfast focal loss